Exceeded Q4 2025 Outlook for Revenue and Adjusted EBITDA, with Strong Adjusted Free Cash FlowModular Activations Increased Year-Over-Year in Q4 ...
Company will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE® (pegcetacoplan ...
This annual earnings news release should be read in conjunction with our 2025 audited consolidated financial statements and management’s discussion and analysis (MD&A), which are all available ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results